# A Dose-response Study of Dietary Resveratrol on Lipid Metabolism Disorder

Study · id `cardio:ct-nct04886297` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04886297](<https://clinicaltrials.gov/study/NCT04886297>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04886297

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

## Technical summary

Registry record NCT04886297. Randomized; double masking; primary purpose prevention. Start 2021-05-01 (actual); primary completion 2022-05-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 168 participants (enrolled count; ClinicalTrials.gov record NCT04886297, source copy `cardio:ctgov-nct04886297-2022-10-27`, retrieved 2026-10-31)
- Started: 2021-05-01 (actual) (ClinicalTrials.gov record NCT04886297, source copy `cardio:ctgov-nct04886297-2022-10-27`, retrieved 2026-10-31)
- Primary completion: 2022-05-30 (actual) (ClinicalTrials.gov record NCT04886297, source copy `cardio:ctgov-nct04886297-2022-10-27`, retrieved 2026-10-31)
- Completion: 2022-09-30 (actual) (ClinicalTrials.gov record NCT04886297, source copy `cardio:ctgov-nct04886297-2022-10-27`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04886297, source copy `cardio:ctgov-nct04886297-2022-10-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04886297-2022-10-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Dose-response Study of Dietary Resveratrol on Lipid Metabolism Disorder
- Condition: Dyslipidemias
- Intervention (Drug): Mega Resveratrol® capsules
- Intervention (Drug): Mega Resveratrol® Placebo capsules
- Lead sponsor: Sun Yat-sen University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Sun Yat-sen University (`cardio:org-sun-yat-sen-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia (`cardio:pubmed-36771199`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9a8f1777522a97cc580829575e10f119cdfcd1f859d82ba1e6995a8669262200
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
